Estrella Immunopharma Warrant
ESLAW
10 hedge funds and large institutions have $2.65M invested in Estrella Immunopharma Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
43% less capital invested
Capital invested by funds: $4.65M → $2.65M (-$2.01M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAMU
SONA Asset Management (US)
New York
|
-$2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $2.02M | – | – | – |
|
|
RCM
2
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $500K | – | – | – |
|
|
KPF
3
K2 Principal Fund
Toronto,
Ontario, Canada
| $32K | – | – | – |
|
|
EFI
4
EHP Funds Inc
Toronto,
Canada
| $30K | +$36.9K | +134,300 | New |
|
|
CH
5
CVI Holdings
Wilmington,
Delaware
| $20K | – | – | – |
|
6
D.E. Shaw & Co
New York
| $20K | – | – | – |
|
7
Hudson Bay Capital Management
Stamford,
Connecticut
| $18K | – | – | – |
|
|
WA
8
Whitebox Advisors
Minneapolis,
Minnesota
| $10K | – | – | – |
|
|
ASM
9
ATW SPAC Management
New York
| $44 | – | – | – |
|
|
SAMU
10
SONA Asset Management (US)
New York
| – | -$2K | -3,540 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$2 | -8 | -4% |
|
ESLAW Hedge Fund Activity: Q1 2022 in Review
10 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q1 2022, worth a combined $2.65M — down 43% from $4.65M a quarter earlier.
Fund positioning in ESLAW was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was SONA Asset Management (US), exiting entirely with an estimated $2K sold.
- 10 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $2.65M of Estrella Immunopharma Warrant stock for Q1 2022, down 43% quarter-over-quarter.
- 1 fund opened new Estrella Immunopharma Warrant positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Estrella Immunopharma Warrant seller in Q1 2022 was SONA Asset Management (US), an estimated $2K sold.
Based on aggregated 13F filings for Q1 2022.